Duffy Null-Associated Absolute Neutrophil Counts and Cancer Clinical Trial Eligibility.
Saved in:
| Title: | Duffy Null-Associated Absolute Neutrophil Counts and Cancer Clinical Trial Eligibility. |
|---|---|
| Authors: | Merz LE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Division of Hematology/Oncology, Department of Medicine, Mass General Brigham, Boston, Massachusetts., Wang Y; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Cronin A; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Sharon E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Walsh TP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Hibbs SP; Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom., Lathan CS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Hantel A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Center for Bioethics, Harvard Medical School, Boston, Massachusetts. |
| Source: | JAMA oncology [JAMA Oncol] 2025 Dec 01; Vol. 11 (12), pp. 1540-1542. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
